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Abstract
Objective: To evaluate associations between quality of life (QOL) and use of ginseng and Ganoderma lucidum (G. lucidum)
among breast cancer survivors.
Methods: Included in this study were 4,149 women with breast cancer who participated in the Shanghai Breast Cancer
Survival Study. Ginseng use was assessed at 6-, 18-, and 36-month post-diagnosis surveys; G. lucidum use was assessed at
the 6- and 36-month surveys. QOL was evaluated at the 6- and 36-month surveys. Multiple linear regression models were
used to examine associations between ginseng and G.lucidum use and QOL assessed at the 36-month survey, with
adjustment for potential confounders and baseline QOL.
Results: At 6 months post-diagnosis, 14.2% of participants reported regular use of ginseng and 58.8% reported use of G.
lucidum. We found no significant associations between ginseng use at 6, 18, and 36 months post-diagnosis and participants’
total QOL score or individual scores for psychological, physical, or social well-being. Post-diagnosis G. lucidum use was
positively associated with social well-being (adjusted mean difference: 1.26; 95% CI: 0.66, 1.86), but was inversely associated
with physical well-being (adjusted mean difference: 21.16; 95% CI: 21.86, 20.47) with a dose-response pattern observed
for cumulative number of times of use (P for trend ,0.001 for both).
Conclusion: We found no evidence that post-diagnosis ginseng use improved the QOL of breast cancer survivors. Post-
diagnosis G. lucidum use was associated with better social well-being scores, but poorer physical well-being scores.
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Introduction
Breast cancer is the most prevalent cancer among women
worldwide, and the number of breast cancer survivors continues to
grow due to advances in early detection and treatment [1,2,3].
Being diagnosed and living with breast cancer is a stressful
experience that affects multiple aspects of patients’ quality of life
(QOL), including psychological, physical, and social well-being
[4,5,6]. Breast cancer patients often use herbal medicines in
conjunction with conventional cancer treatments, to relieve
cancer-related symptoms and boost their immune system, with
the expectation of improved QOL [7,8,9]. However, whether
post-diagnosis use of herbal medicines indeed improves breast
cancer survivors’ QOL remains to be determined.
Ginseng and Ganoderma lucidum (G. lucidum) are two herbal
remedies that have been widely used to proactively promote
health, vitality, and longevity in Asia [10,11,12]. In recent years,
ginseng use has gained popularity in Western countries. For
instance, ginseng has been included in the Pharmacopoeias of
Germany, Austria, and the United Kingdom [13]; in the United
States, ginseng has been ranked as the fourth top-selling herbal
medicine [14]. However, evidence-based information on the
association between ginseng use and QOL is inconsistent and
limited, particularly among patients with cancer [13,15,16]. G.
lucidum is a popular medicinal mushroom. Besides being used for
promoting health, it is also used for prevention or treatment of a
variety of diseases, including cancer [12]. We have found that G.
lucidum is one of the most commonly used herbs among Chinese
breast cancer survivors [17]. Several in vitro studies have reported
that G. lucidum has anti-cancer properties [12,18,19,20]. However,
to date, no clinical or epidemiological studies have described the
influence of G. lucidum use after cancer diagnosis on clinical
outcomes or survivor’s QOL.
The purpose of this study was to systematically evaluate
associations of ginseng and G. lucidum use with the QOL of breast
cancer survivors during the first 36 months after diagnosis in a
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e39343large, population-based cohort study of breast cancer in Shanghai,
China. This study provides a prospective view of the association
between ginseng and G. lucidum use and QOL.
Materials and Methods
Ethics Statement
The study was approved by the institutional review boards of all
participating institutions: the Shanghai Municipal Center for
Disease Control and Prevention and Vanderbilt University.
Written, informed consent was obtained from all study partici-
pants.
Study Population
Study participants were breast cancer patients who enrolled in
the Shanghai Breast Cancer Survival Study (SBCSS), a popula-
tion-based, prospective study conducted in Shanghai, China.
Details on the study’s design and implementation have been
described previously [21,22,23,24]. Briefly, through the popula-
tion-based Shanghai Cancer Registry, 6,299 women aged 20–75
years with breast cancer were identified between March 2002 and
April 2006; 5,042 (80%) provided written informed consent and
enrolled in the study approximately 6 months (range: 3–11
months) after cancer diagnosis. The cohort was followed through
in-person interviews at 18 and 36 months post-diagnosis. A total of
4,572 completed the 18-month interview and 4,149 completed the
36-month interview. Included in the present study were 4,149
participants who completed the baseline survey (at 6 months after
diagnosis) and the 36-month interview with QOL information.
There were no significant differences in socio-demographics
between all participants enrolled (n=5,042) and those included
in the present study (n=4,149) (data not shown).
Data Collection
The baseline in-person interviews were conducted by trained
interviewers using structured questionnaires that covered demo-
graphic characteristics, menstrual and reproductive history,
dietary intake, use of complementary and alternative medicine
(CAM), exercise participation, and family history of breast cancer.
Height, weight, waist circumference, and hip circumference were
measured according to a standard protocol. Body mass index
(BMI) was calculated as weight (in kilograms) divided by height (in
meters) squared. Clinical information collected included tumor-
node metastasis (TNM) stage at diagnosis, estrogen receptor (ER)
and progesterone receptor (PR) status, and primary cancer
treatments received. In addition, inpatient medical charts were
reviewed to verify diagnosis and therapy information. Follow-up
interviews were conducted at 18 and 36 months after diagnosis to
obtain information on disease recurrence, survival status, and
QOL and to update information on active lifestyle factors, use of
supplements, current health condition, and medication use. The
Charlson comorbidity index was calculated based on a validated
comorbidity scoring system [25] and the diagnostic codes from the
International Classification of Disease, Ninth Revision, Clinical
Modification [26].
For each participant, information on regular use (at least once a
week for one month or longer) of supplements, including ginseng
and G. lucidum, fish oil, shark cartilage, melatonin, lecithin, and
vitamin supplements after diagnosis, duration (in months) of use,
and frequency (times/month) was obtained. At the baseline survey,
participants reported use during the period after breast cancer
diagnosis. At subsequent surveys, participants reported supplement
use since the last interview (i.e., for the preceding 12 months and
18 months). Information on types of ginseng and ginseng products,
including red or white Asian ginseng, American ginseng, and
ginseng products (tablets, capsules, extracts, etc.), was collected.
Data on G. lucidum use were only collected at the 6- and 36-month
surveys. In the current study, we focused on evaluation of ginseng
or G. lucidum use and QOL, because these were the most common
herbal preparations taken by breast cancer patients in our study
population and they are specifically labeled as aids for cancer
recovery on the market.
The average frequency of use after diagnosis (times/month) was
calculated. We computed the cumulative number of times of use
after diagnosis as ‘‘duration (months) of use 6frequency (times/
month)’’ summed over three surveys (for ginseng) or two surveys
(for G. lucidum). We also derived patterns of ginseng or G. lucidum
use according to information gathered at multiple surveys (the 6-,
18-, and 36-month post-diagnosis surveys for ginseng and the 6-
and 36-month post-diagnosis surveys for G. lucidum) as follows: 1)
‘‘never users’’ refers to participants with no use reported at any
survey; 2) ‘‘quitters’’ refers to participants who reported use at
earlier survey(s), but stopped use subsequently; 3) ‘‘pick-up users’’
refers to participants who reported use only after the baseline or
18-month surveys; and 4) ‘‘consistent users’’ refers to participants
who reported use of ginseng or G. lucidum on all relevant follow-up
surveys (three for ginseng; two for G. lucidum).
Two previously validated instruments for assessment of QOL,
the General Quality of Life Inventory-74 (GQOLI-74, used in the
first set of 2,500 SBCSS participants) and the Short-Form Health
Survey (SF-36, Chinese version, used in the second set of 2,542
SBCSS participants), were used to assess health-related QOL
among participants at the baseline survey [24]. The current
analysis includes 1,845 survivors who took the GQOLI-74, and
2,304 survivors who took the SF-36 at the baseline survey. At the
36-month interview, all survivors’ QOL was assessed using the
GQOLI-74. The GQOLI-74 is based on the World Health
Organization’s Quality of Life Assessment Instrument and was
modified for use in Chinese populations. The GQOLI-74,
described in detail in our previous studies [22,27], includes 20
facets, a global QOL assessment, and covers the following 4
domains: physical well-being, psychological well-being, social well-
being, and material well-being. Participants’ responses were
converted to a score on a 0–100 scale for each domain and facet;
higher scores reflected higher QOL. In the present study, the
sexual functioning score was excluded from the calculation of
physical well-being and total QOL for the GQOLI-74 instrument,
because ,93% of participants at the baseline survey and ,92% at
the 36-month survey reported ‘‘none or little’’ sexual activity
during the 2–4 weeks before the interview. The SF-36 is composed
of 16 questions with 36 items in eight health subscales. Each
subscale and summary scale has a value ranging from 0 to 100.
The validity of SF-36 has been evaluated in the Chinese
population [28,29].
Statistical Analysis
The primary outcomes of this analysis included total QOL, four
well-being domains, and all facets except for the sexual functioning
score based on the QOL assessment at the 36-month survey.
Differences in socio-demographic and clinical characteristics by
ginseng and G. lucidum use at baseline were evaluated using
Student’s t test for continuous variables and the x
2 test for
categorical variables. Multiple linear regression models were used
to estimate the mean differences and 95% confidence intervals
(95% CI) for QOL scores across ginseng and G. lucidum categories.
The following covariates were included in the multivariate models:
age at diagnosis, educational level, income, marital status, exercise
participation, tea consumption, menopausal status, menopausal
Ginseng, G. lucidum, Breast Cancer, and QOL
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ment use, traditional Chinese medicine (TCM) use, TNM stage,
type of surgery, chemotherapy, radiotherapy, tamoxifen use, ER/
PR status, recurrence/metastasis, and baseline total QOL score.
We found no clear evidence of collinearity (i.e., variance inflation
factor .10) for the variables included in the final model.
We evaluated associations of patterns of use of ginseng or G.
lucidum, average frequency, and cumulative number of times of
ginseng/G. lucidum use and QOL at 36 months post-diagnosis. In
addition, analyses stratified by baseline QOL, comorbidity,
radiotherapy, and ER/PR status were carried out. Tests for
interaction were conducted by comparing the model with both
interactive terms and main effect terms with the model with only
main effect terms. Tests for trend in the analyses were completed
by entering the categorical variables as continuous parameters in
the corresponding models.
All reported P values are two-sided, and the significance levels
were set at P,0.05. All statistical analyses were performed by
using SAS software, version 9.2 (SAS Institute Inc., Cary, North
Carolina).
Table 1. Ginseng and G. lucidum intake at the 6-month post-diagnosis survey (baseline) by demographic, lifestyle, and medical
characteristics, Shanghai Breast Cancer Survival Study, 2002–2008.
Characteristics Total (N=4,149) Ginseng G. lucidum
No (N=3,562) Yes (N=587) No (N=1,709) Yes (N=2,440)
Age at diagnosis (year) 53.8(10.0) 53.4 (9.9) 55.9(10.5)* 55.4(10.6) 52.6(9.4)*
TCM (%) 77.2 78.1 71.4* 72.9 80.2*
Vitamin supplement use (%) 36.8 35.4 45.5* 33.8 38.9*
Ginseng use (%) 14.2 15.6 13.1*
G. lucidum use (%) 58.8 59.5 54.5*
Other supplement use (%) 6.31 5.42 11.75* 6.20 6.39
Educational level (%)
No formal education or elementary school only 12.0 11.5 15.0 18.5 7.4
Middle or high school 72.6 73.0 69.9 70.2 74.3
College or higher 15.5 15.5 15.2 11.3 18.3*
Income (yuan/month per capita)
, 1000 57.4 57.0 59.8 66.7 50.8
1000–1999 31.0 31.3 29.1 25.3 35.0
$ 2000 11.6 11.7 11.1 8.0 14.2*
BMI 24.2(3.4) 24.1(3.4) 24.4(3.5) 24.4(3.5) 24.0(3.3)*
Marital status: married (%) 87.6 87.9 85.5 84.1 90.0*
Post-menopausal (%) 48.0 48.9 42.4* 42.4 51.9*
Menopausal symptoms (%) 64.6 65.0 62.0 60.9 67.2*
Charlson comorbidity index $1 (%) 20.6 19.9 24.9* 23.1 18.9*
Exercise participation (%) 65.7 65.7 65.4 63.6 67.1*
Regular alcohol consumption (%) 96.8 3.1 3.9 3.0 3.3
Regular cigarette smoking (%) 97.4 2.4 3.9* 3.9 1.8*
Regular tea consumption (%) 23.5 23.3 24.5 22.1 24.4
Mastectomy (%) 94.4 94.8 92.5* 94.0 94.8
Chemotherapy (%) 91.0 91.4 88.3* 86.4 94.2*
Radiotherapy (%) 30.5 31.0 27.4 26.6 33.3*
Tamoxifen use (%) 53.5 52.8 57.4* 54.5 52.8
TNM stage (%)
0–I 38.3 38.9 34.6 36.8 39.3
IIA 33.2 32.8 36.1 33.7 33.0
IIB+ 16.0 16.1 15.2 16.5 15.6
III-IV 8.0 7.9 8.5 7.8 8.1
Unknown 4.5 4.3 5.6 5.3 4.0
Total QOL Score 59.6(14.0) 59.4(14.1) 60.7(13.0)* 59.6(13.9) 59.6(14.0)
Note: Abbreviations: TCM, traditional Chinese medicine; QOL, quality of life.
Values are presented as means (standard deviation) or percentages.
*P value ,0.05, for tests of the difference between women with and without regular ginseng/G. lucidum use.
doi:10.1371/journal.pone.0039343.t001
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Of the 4,149 participants who completed the 36-month survey
(range: 32.7–44.4 months after cancer diagnosis), 14.2%, 12.8%,
and 10.9% reported ginseng use at the 6-, 18-, and 36-month
surveys, respectively; and 58.8% and 36.2% reported G. lucidum
use at the 6- and 36-month surveys, respectively.
Demographic, lifestyle, and medical characteristics of all
participants and by ginseng or G. lucidum use at the baseline
interview are presented in Table 1. The mean age at diagnosis was
53.8 years (610.0 SD). At baseline, ginseng users, compared with
non-users, were older and were more likely to take vitamins and
other supplements, have a higher comorbidity index, be regular
cigarette smokers, have undergone tamoxifen treatment, and
report a better overall QOL at study enrollment, but were less
likely to use G. lucidum or other TCM, be post-menopausal, or to
have undergone mastectomy or chemotherapy. Compared with
non-users of G. lucidum, G. lucidum users were younger and were
more likely to use vitamins and TCM, have better education and
higher income, be married, be post-menopausal, have menopausal
symptoms, have a lower comorbidity index, regularly participate
in exercise, have received chemotherapy and radiotherapy, and
were less likely to be regular cigarette smokers.
We found no overall associations between ginseng use during
the three time periods we assessed and total QOL score or scores
for the physical, psychological, social, or material well-being
domains measured at the 36-month follow-up (Table 2). Sub-
domain analysis showed that a lower score for daily living
capability and a higher score for community services was
associated with ginseng use at the baseline survey, a higher score
for body/self-image was associated with ginseng use assessed at 18-
month survey, and a lower score for the financial situation
subdomain was associated with ginseng use assessed at the 36-
month survey.
G. lucidum use at the 6- and 36-month surveys was not
significantly associated with total QOL or psychological well-
being at the 36-month follow-up (Table 3). However, we observed
significant associations with higher scores for social well-being and
Table 3. Total, domain and facet QOL scores at 36 months after cancer diagnosis in association with G. lucidum use assessed at 6
and 36 months after cancer diagnosis, Shanghai Breast Cancer Survival Study, 2002–2008.
QOL at 36 months after diagnosis 6-month post-diagnosis survey (baseline) 36-month post-diagnosis survey
No (N=1,709) Yes (N=2,440)
No
(N=2,648) Yes (N=1,501)
Score
Mean
difference
a 95% CI Score Mean difference
a 95% CI
Total QOL score 62.32 0.31 20.17,0.78 62.82 0.08 20.40,0.56
Physical well-being 65.33 20.68 21.34, 20.02* 65.77 21.32 21.99, 20.66*
Sleep and energy 61.40 20.86 21.82,0.10 61.72 21.59 22.57, 20.62*
Physical discomfort 66.98 21.53 22.59,-0.48* 67.06 21.89 22.96, 20.82*
Eating function 68.53 20.49 21.32,0.33 68.87 21.11 21.94, 20.28*
Daily living capability 64.44 0.16 20.57,0.89 65.42 20.69 21.42,0.05
Psychological well-being 68.73 20.10 20.71,0.50 68.88 0.21 20.40,0.82
Psychological distress 77.95 20.29 21.06,0.49 77.91 0.00 20.78,0.79
Negative feelings 71.35 20.71 21.45,0.03 71.01 0.13 20.61,0.88
Positive feelings 67.48 20.64 21.69,0.41 67.39 0.02 21.04,1.08
Cognition functioning 64.12 0.36 20.48,1.19 64.93 0.04 20.81,0.89
Body/Self-image 62.74 0.77 0.01,1.52* 63.21 0.78 0.02,1.55*
Social well-being 63.88 1.20 0.62,1.77* 64.84 0.85 0.27,1.43*
Social support 61.84 2.57 1.48,3.67* 63.48 2.29 1.19,3.40*
Interpersonal relationships 72.41 1.75 0.99,2.51* 73.40 1.29 0.52,2.06*
Work and study capacity 56.14 0.70 20.02,1.42 57.11 0.43 20.30,1.17
Recreational and leisure activities 56.95 0.43 20.32,1.18 57.44 20.03 20.80,0.73
Marriage and family 72.11 0.54 20.34,1.41 72.82 0.23 20.65,1.11
Material well-being 50.36 0.81 0.08,1.54* 50.78 0.52 20.21,1.26
Housing situation 66.87 1.45 0.32,2.58* 67.37 1.40 0.26,2.54*
Community services 43.11 1.17 0.18,2.16* 43.82 0.13 20.87,1.13
Living function 49.74 0.13 21.16,1.42 49.86 0.52 20.79,1.82
Financial situation 41.73 0.47 20.63,1.57 42.09 0.06 21.05,1.18
General QOL 58.25 20.01 20.79,0.76 58.79 20.50 21.29,0.28
Note: Abbreviations: CI, confidence interval; QOL, quality of life.
aObtained from multiple linear regression models adjusted for age at diagnosis, educational level, income, marital status, exercise participation, tea consumption,
menopausal status, menopausal symptoms, comorbidity, body mass index (BMI), vitamin supplement use, traditional Chinese medicine (TCM) use, TNM stage, type of
surgery, chemotherapy, radiotherapy, tamoxifen use, ER/PR status, recurrence/metastasis, and baseline total QOL.
*P value ,0.05.
doi:10.1371/journal.pone.0039343.t003
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Specifically, G. lucidum users had higher scores for self-image, social
support, interpersonal relationships, housing situation, and com-
munity services, but lower scores for sleep and energy, physical
discomfort, and eating function.
We also evaluated associations of pattern of use, average
frequency of use, and cumulative number of times of use of
ginseng or G. lucidum since cancer diagnosis with QOL at the 36-
month survey (Table 4). In general, there were no significant
differences in total or subscale QOL scores between participants
who never used ginseng regularly and those who ever used ginseng
regularly after cancer diagnosis. We found that ginseng users in the
‘‘consistent’’ group, compared with never-users, had a lower score
for physical well-being, which reached borderline statistical
significance (adjusted mean difference: 20.71; 95% CI: 22.49,
0.07). A borderline significant association between higher
Table 4. Adjusted mean differences
a in total QOL and domain QOL scores assessed at 36 months after cancer diagnosis by pattern
and cumulative level of ginseng and G. lucidum use post-diagnosis, Shanghai Breast Cancer Survival Study, 2002–2008.
Status of use No. Total QOL score Physical well-being Psychological well-being Social well-being
Mean
difference 95% CI
Mean
difference 95% CI
Mean
difference 95% CI
Mean
difference 95% CI
Ginseng
Ever use after diagnosis
Never users 3132 Ref – Ref – Ref – Ref –
Ever users 1017 20.03 20.56,0.51 20.25 20.99,0.50 20.13 20.81,0.55 0.09 20.56,0.74
Quitters 399 0.08 20.69,0.86 -0.61 21.68,0.47 20.04 21.02,0.94 20.01 20.95,0.93
Pick-up users 265 0.22 20.72,1.16 0.27 21.04,0.57 0.39 20.80,1.59 0.40 20.74,1.54
Consistent users 136 20.57 21.85,0.71 20.71 22.49,0.07 20.61 22.24,1.02 20.32 21.88,1.23
Other 217 20.19 21.22,0.84 0.10 21.33,0.53 20.65 21.95,0.66 0.17 21.08,1.41
Average frequency of use after diagnosis
Never 3132 Ref – Ref – Ref – Ref –
#11.6 times/m 505 0.02 20.68,0.73 0.25 20.73,1.22 20.45 21.34,0.45 0.29 20.56,1.14
.11.6 times/m 504 20.16 20.87,0.54 20.92 21.90,0.05 0.12 20.77,1.02 20.19 21.04,0.67
P trend 0.70 0.14 0.93 0.87
Cumulative number of times of use after diagnosis
Never 3132 Ref – Ref – Ref – Ref –
#156 times 508 0.33 20.37,1.03 0.31 20.66,1.28 20.05 20.94,0.84 0.54 20.31,1.39
.156 times 508 20.37 21.08,0.33 20.80 21.78,0.18 20.20 21.10,0.70 20.35 21.21,0.51
P trend 0.54 0.22 0.68 0.77
G. lucidum
Ever use after diagnosis
Never users 1367 Ref – Ref – Ref – Ref –
Ever users 2782 0.23 20.26,0.73 21.16 21.86,20.47 0.05 20.59,0.68 1.26 0.66,1.86
Quitters 1281 0.26 20.32,0.84 20.63 21.43,0.17 20.08 20.82,0.65 1.10 0.40,1.80
Pick-up users 342 20.10 20.99,0.78 21.82 23.04,20.59 0.44 20.68,1.57 0.70 20.37,1.77
Consistent users 1159 0.31 20.29,0.92 21.59 22.43,20.76 0.08 20.69,0.85 1.64 0.91,2.37
Average frequency of use after diagnosis
Never 1367 Ref – Ref – Ref – Ref –
,31.8 times/m 1388 20.07 20.64,0.49 21.46 22.25,20.68 20.28 21.00,0.44 0.91 0.22,1.59
$31.8 times/m 1388 0.56 20.01,1.13 20.86 21.66,20.06 0.40 -0.33,1.13 1.64 0.95,2.34
P trend 0.05 0.04 0.27 ,0.0001
Cumulative number of times of use after diagnosis
Never 1367 Ref – Ref – Ref – Ref –
#360 times 1457 0.13 20.43,0.68 20.91 21.68,20.14 20.08 20.79,0.63 1.04 0.36,1.71
.360 times 1324 0.35 20.23,0.94 21.49 22.30, 20.68 0.20 20.54,0.94 1.52 0.81,2.23
P trend 0.24 0.0003 0.60 ,0.0001
Note: Abbreviations: CI, confidence interval; QOL, quality of life.
aObtained from multiple linear regression models adjusted for age at diagnosis, educational level, income, marital status, exercise participation, tea consumption,
menopausal status, menopausal symptoms, comorbidity, body mass index (BMI), vitamin supplement use, traditional Chinese medicine (TCM) use, TNM stage, type of
surgery, chemotherapy, radiotherapy, tamoxifen use, ER/PR status, recurrence/metastasis, and baseline total QOL. Participants who never reported having regularly
used ginseng or G. lucidum on all three surveys served as the reference.
doi:10.1371/journal.pone.0039343.t004
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well-being was also observed (adjusted mean difference: 20.92
(95% CI: 21.90, 0.05).
Higher frequency ($31.8 times/month) of G. lucidum use after
diagnosis was related to higher total QOL scores (P for trend
=0.05) and higher social well-being scores (P for trend ,0.0001).
A higher cumulative number of times (.360 times) of G. lucidum
use after diagnosis was positively associated with social well-being
(P for trend ,0.0001; adjusted mean difference: 1.52; 95% CI:
0.81, 2.23) and inversely associated with physical well-being (P for
trend =0.0003; adjusted mean difference: 21.49; 95% CI: 22.30,
20.68). These associations were predominantly observed among
‘‘pick-up’’ users and ‘‘consistent’’ users (Table 4).
Further analyses stratified by baseline QOL showed that the
associations between regular ginseng/G. lucidum use and QOL at
the 36-month follow-up were not modified by baseline QOL total
score (interaction term test: all P .0.05) (Table 5). Similarly, we
found no interaction of comorbidity, radiotherapy, or ER/PR
status with regular use of ginseng or G. lucidum among the study
participants (data not shown).
Discussion
This is the first comprehensive study to evaluate the effects of
regular use of ginseng and G. lucidum as a complementary therapy
at different time points after cancer diagnosis on breast cancer
survivor’s QOL in a large, population-based cohort study. We
found no evidence that ginseng use post-diagnosis was associated
with improved QOL at the 36-month follow-up. Survivors who
used G. lucidum regularly after cancer diagnosis reported a higher
score for social well-being, but a lower score for physical well-
being, compared with non-users. These differences were more
apparent for higher frequency and cumulative number of times of
use during the entire follow-up period.
Ginseng has been used to maintain natural energy, increase
physical and psychomotor performance, and improve mood and
general health [13]. There are several types of ginseng, including
Asian ginseng (Panax ginseng) and American ginseng (P. quinquefo-
lius); the major active constituents are ginsenosides. Over 80% of
our study population used American ginseng. In vitro experiments
and in vivo animal studies have reported that ginsenosides have a
variety of beneficial effects, including immunodulatory, anti-stress,
anti-fatigue, and anti-carcinogenic effects [30,31,32]. However, in
human studies, findings on the effects of ginseng on health-related
QOL are mixed [13,15,16]. A systematic review by Vogler et al.
summarized several randomized clinical trials and found contra-
dictory results for ginseng ability to improve physical performance
and immune function [16]. Coleman et al. reviewed 9 clinical
trials and concluded that improvement in overall health-related
QOL cannot be attributed to P. ginseng, although various facets of
QOL had improved [13].
There is a paucity of data from epidemiological studies
regarding the effects of ginseng use on QOL among cancer
patients. Our previous studies have shown that ginseng use,
particularly current use at the fourth year post-diagnosis, was
positively associated with QOL scores, with the strongest effects in
the psychological and social well-being domains [15]. In the
present study, however, we found no significant positive associa-
tions between post-diagnosis ginseng use and survivors’ QOL at
the 36-month follow-up. There are several potential reasons for
this discrepancy. First, the design of previous studies differed from
the present study, which is a prospective survival study specifically
designed to investigate post-diagnostic lifestyle and CAM use and
collected relevant information at multiple, pre-determined time
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study was an ad hoc follow-up of breast cancer patients enrolled in
a case-control study, for which exposure data were collected at one
time point after cancer diagnosis (approximately 48 months).
Second, the prevalence of ginseng use among breast cancer
survivors was substantially lower in the current study compared
with the previous study, which may have obscured the association
between ginseng use and breast cancer survivors’ QOL. In the
previous study, 62.8% of women with breast cancer reported post-
diagnosis ginseng use, and 30.6% were current users. In the
present study, 14.2% of participants were ginseng users at baseline
and 10.9% were ginseng users at the 36-month follow-up. In
addition, the timing of the QOL assessment also differed between
our two studies. In our earlier study, QOL was assessed only once
at the fourth year post-diagnosis, while in the present study, QOL
was assessed at 6 and 36 months post-diagnosis and the association
of QOL at the 36-month survey with ginseng use was adjusted for
the baseline QOL score.
G. lucidum was the most popular herbal remedy used by our
study participants [17]. The prevalence of use among women with
breast cancer increased during the decade prior to the current
study’s recruitment period from 18.9% among breast cancer cases
enrolled in our case-control study (1996–1998) [33] to 58.4%
(2002–2006) [17]. In the present study, 58% of participants
reported G. lucidum use at the 36-month survey. To date, over one
hundred species of oxygenated triterpenes have been isolated from
G. lucidum. G. lucidum has been reported to have many biological
activities, such as histamine release-inhibitory action, immuno-
modulatory activity, antitumor cytokines acting on inhibition of
leukemic-cell growth, and differentiation inducing activity [10].
In vitro experiments have shown that G. lucidum can inhibit
proliferation, invasive behavior, and growth of tumor cells, and
induce tumor cell apoptosis [12,18,19,20,34,35]. However, no
study has reported on the effects of G. lucidum use on clinical
outcomes and/or QOL among breast cancer survivors. In the
present study, we found that G. lucidum use after breast cancer
diagnosis was associated with a higher score for social well-being,
but a lower score for physical well-being. As a result, the overall
QOL score was not significantly associated with G. lucidum use.
The underlying mechanisms for these associations are unclear.
The improvement of social well-being may reflect better financial
and social support, while the reduced physical well-being score
may suggest that either G. lucidum use negatively influenced
patients’ physical well-being or patients with low physical well-
being were more likely to seek G. lucidum as complementary
treatment. Given the popularity of G. lucidum use among women
with breast cancer, more studies should be conducted to clarify its
effects on breast cancer survivors’ QOL.
Our study has several strengths. It is the first population-based,
longitudinal, prospective study with a large enough sample size to
investigate relationships between the use of ginseng and G. lucidum
after diagnosis and QOL among breast cancer survivors. Multiple
assessments improved the quality of both the exposure and
outcome information. Selection bias was largely minimized due to
the high response and follow-up rates. The detailed data on socio-
demographic, lifestyle, and known clinical prognostic factors that
we collected allowed a detailed adjustment for potential con-
founding factors. However, several limitations of our study should
also be noted. First, information about pre-diagnosis use of ginseng
and G. lucidum was not available; thus, we were unable to evaluate
the influence of pre-diagnosis ginseng and G. lucidum use on QOL.
Second, the brand of ginseng and G. lucidum products and specific
dosages used may affect their effectiveness, but our study did not
collect this information. Third, although sexual functioning is an
important component of QOL, we were not able to evaluate its
association with ginseng and G. lucidum use, because of the very
small number of participants who reported being sexually active,
which is likely due to the fact that the subject of ‘‘sexual
functioning’’ is considered to be very private in Eastern cultures.
In summary, our study found no evidence that ginseng use after
breast cancer diagnosis improved survivors’ QOL during the first
three years post-diagnosis. G. lucidum use after cancer diagnosis was
associated with better social well-being, but poorer physical well-
being. Further studies are needed to investigate the benefits and
safety of ginseng and G. lucidum use among longer-term cancer
survivors.
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